Health Care·Biotechnology·$7.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | -2.04% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.23 | N/A | -2.04% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding the company's financial outlook. They highlighted ongoing challenges but did not elaborate on future plans.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges in achieving profitability.
This earnings report indicates that Halozyme Therapeutics is still facing challenges, particularly in achieving profitability, as reflected in the missed EPS. The stock reacted negatively, dropping 1.06%, likely due to the lack of guidance and ongoing concerns about financial performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CHENIERE ENERGY PART
Aug 7, 2017